As of 2025-07-06, the EV/EBITDA ratio of Vivoryon Therapeutics NV (VVY.AS) is -0.89. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. VVY.AS's latest enterprise value is 29.06 mil EUR. VVY.AS's TTM EBITDA according to its financial statements is -32.81 mil EUR. Dividing these 2 quantities gives us the above VVY.AS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2025-06-16 | -1.01 |
| 2025-06-13 | -1.02 |
| 2025-06-12 | -1.06 |
| 2025-06-11 | -1.07 |
| 2025-06-10 | -1.07 |
| 2025-06-09 | -1.09 |
| 2025-06-06 | -1.08 |
| 2025-06-05 | -1.06 |
| 2025-06-04 | -1.07 |
| 2025-06-03 | -1.07 |
| 2025-06-02 | -1.08 |
| 2025-05-30 | -1.08 |
| 2025-05-29 | -1.09 |
| 2025-05-28 | -1.08 |
| 2025-05-27 | -1.10 |
| 2025-05-26 | -1.08 |
| 2025-05-23 | -1.10 |
| 2025-05-22 | -1.12 |
| 2025-05-21 | -1.15 |
| 2025-05-20 | -1.14 |
| 2025-05-19 | -1.12 |
| 2025-05-16 | -1.09 |
| 2025-05-15 | -1.09 |
| 2025-05-14 | -1.11 |
| 2025-05-13 | -1.11 |
| 2025-05-12 | -1.12 |
| 2025-05-09 | -1.12 |
| 2025-05-08 | -1.12 |
| 2025-05-07 | -1.10 |
| 2025-05-06 | -1.11 |
| 2025-05-05 | -1.11 |
| 2025-05-02 | -1.14 |
| 2025-04-30 | -1.12 |
| 2025-04-29 | -1.14 |
| 2025-04-28 | -1.15 |
| 2025-04-25 | -1.13 |
| 2025-04-24 | -1.16 |
| 2025-04-23 | -1.14 |
| 2025-04-22 | -1.14 |
| 2025-04-17 | -1.11 |
| 2025-04-16 | -1.07 |
| 2025-04-15 | -1.08 |
| 2025-04-14 | -1.07 |
| 2025-04-11 | -1.12 |
| 2025-04-10 | -1.15 |
| 2025-04-09 | -1.17 |
| 2025-04-08 | -1.17 |
| 2025-04-07 | -1.08 |
| 2025-04-04 | -1.11 |
| 2025-04-03 | -1.18 |